Secukinumab Treatment of moderate to severe Plaque Psoriasis in the clinical Routine Care: Baseline Data from the PROSPECT Study on Psoriasis Pre-treatment

Von Kiedrowski R, Korber A, Kraehn-Senftleben G, Sticherling M, Lange L, Bachhuber T, Kasparek TR, Augustin M, Thaci D, Amon U (2017)

Publication Type: Conference contribution

Publication year: 2017

Journal

Journal der Deutschen Dermatologischen Gesellschaft Wiley-Blackwell

Book Volume: 15

Pages Range: 138-138

Authors with CRIS profile

Michael Sticherling Professur für Dermatologie

Involved external institutions

Universitätsklinikum Essen DE Germany (DE) Universitätsklinikum Hamburg-Eppendorf (UKE) DE Germany (DE) Universitätsklinikum Schleswig-Holstein (UKSH) DE Germany (DE) Novartis AG CH Switzerland (CH) HAUTZENTRUM Donau Alb, Hautarzt in Blaubeuren und Neu-Ulm Dr. Gertaud Krähn-Senftleben und Dr. Judith Mair DE Germany (DE) Internationales Hautarztzentrum GbR DE Germany (DE) Dermatologische Spezialpraxis DE Germany (DE)

How to cite

APA:

Von Kiedrowski, R., Korber, A., Kraehn-Senftleben, G., Sticherling, M., Lange, L., Bachhuber, T.,... Amon, U. (2017). Secukinumab Treatment of moderate to severe Plaque Psoriasis in the clinical Routine Care: Baseline Data from the PROSPECT Study on Psoriasis Pre-treatment. (pp. 138-138).

MLA:

Von Kiedrowski, R., et al. "Secukinumab Treatment of moderate to severe Plaque Psoriasis in the clinical Routine Care: Baseline Data from the PROSPECT Study on Psoriasis Pre-treatment." 2017. 138-138.

BibTeX: Download